It was a busy Wednesday for Eagle IP! Last Wednesday (15 Feb), our Vice President and Principal, Jennifer Che, also gave a talk at the HKU Technology Transfer Office’s “Technology Transfer Primer” webinar series, sharing with the HKU community the 101s of patents and top tips to protect IP.



我们的过去活动

Recommended Insights

Announcement: Implementation Regulations (Rules) of the Chinese Patent Law have been Approved

2023年11月10日
On November 3rd, 2023, the Premier of the State Council, Li Qiang, chaired a regular meeting where the "Implementation Regulations of the Patent Law of the People's Republic of China (Revised Draft)" was reviewed and approved. This is great news, as we have been waiting quite some time for these Regulations (Rules) to be approved (see […]

What Kind of Damage Awards Can You Get in China?

2022年6月16日
Is it worth filing for a patent in China? What kind of damage awards can you get? Pharma companies care more about injunction than damage awards, since it’s quite unlikely that any damage award can compensate for the large amounts of money that may be lost for patent infringement. Chinese courts often issue injunctions in […]

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

2022年9月21日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

Is it Sufficient to Claim an Antibody only by Describing its Antigen?

2018年11月12日
Things may be brewing with respect to antibody inventions. Just how much description is sufficient? After losing in the Federal Circuit, Amgen has decided to ask the US Supreme Court to weigh in on a standard that could vastly influence the pharmaceutical and biotech industry. The story relates to Repatha™, an LDL-lowering drug from Amgen […]
Top crossarrow-right